Rubicon Founders LLC Invests $153.64 Billion in Privia Health Group, Inc. $PRVA

Rubicon Founders LLC purchased a new stake in shares of Privia Health Group, Inc. (NASDAQ:PRVA) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 5,971,079 shares of the company’s stock, valued at approximately $153,635,863,000. Privia Health Group makes up approximately 78.2% of Rubicon Founders LLC’s investment portfolio, making the stock its biggest position.

Other institutional investors also recently modified their holdings of the company. GAMMA Investing LLC increased its holdings in Privia Health Group by 14.0% in the 2nd quarter. GAMMA Investing LLC now owns 4,819 shares of the company’s stock worth $124,000 after buying an additional 592 shares in the last quarter. PNC Financial Services Group Inc. raised its position in Privia Health Group by 8.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 10,361 shares of the company’s stock worth $213,000 after buying an additional 840 shares during the last quarter. ProShare Advisors LLC lifted its stake in Privia Health Group by 4.1% during the 4th quarter. ProShare Advisors LLC now owns 22,576 shares of the company’s stock valued at $535,000 after acquiring an additional 898 shares during the period. Vanguard Personalized Indexing Management LLC lifted its stake in Privia Health Group by 5.9% during the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 16,250 shares of the company’s stock valued at $385,000 after acquiring an additional 903 shares during the period. Finally, Hantz Financial Services Inc. boosted its holdings in shares of Privia Health Group by 456.2% during the 4th quarter. Hantz Financial Services Inc. now owns 1,129 shares of the company’s stock valued at $27,000 after acquiring an additional 926 shares during the last quarter. 94.48% of the stock is owned by hedge funds and other institutional investors.

Privia Health Group Stock Performance

PRVA stock opened at $21.02 on Tuesday. The company has a market cap of $2.68 billion, a price-to-earnings ratio of 100.10, a P/E/G ratio of 1.67 and a beta of 0.85. The business’s 50-day moving average is $24.54 and its two-hundred day moving average is $23.22. Privia Health Group, Inc. has a fifty-two week low of $19.53 and a fifty-two week high of $28.82.

Privia Health Group (NASDAQ:PRVA) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.07 by $0.12. Privia Health Group had a return on equity of 3.52% and a net margin of 1.19%.The business had revenue of $632.63 million during the quarter, compared to the consensus estimate of $597.33 million. During the same period in the previous year, the company posted $0.24 EPS. The business’s quarterly revenue was up 21.4% compared to the same quarter last year. Equities analysts predict that Privia Health Group, Inc. will post 0.27 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have recently commented on PRVA. Citigroup reiterated a “buy” rating on shares of Privia Health Group in a research note on Thursday, July 23rd. Canaccord Genuity Group set a $32.00 price objective on shares of Privia Health Group in a research report on Friday, August 7th. Barclays dropped their target price on shares of Privia Health Group from $25.00 to $24.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 26th. Weiss Ratings raised shares of Privia Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, July 2nd. Finally, Zacks Research upgraded shares of Privia Health Group from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 5th. Eleven equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $31.00.

Insider Buying and Selling

In related news, CFO David Mountcastle sold 24,734 shares of the firm’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $27.50, for a total value of $680,185.00. Following the transaction, the chief financial officer owned 186,728 shares of the company’s stock, valued at approximately $5,135,020. This trade represents a 11.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew Shawn Morris sold 88,110 shares of the business’s stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $25.33, for a total transaction of $2,231,826.30. Following the sale, the director owned 76,651 shares of the company’s stock, valued at $1,941,569.83. This trade represents a 53.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 327,886 shares of company stock worth $8,628,256. 5.70% of the stock is currently owned by insiders.

Privia Health Group Company Profile

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.